Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators.
Multi-scaled transcriptomics of chronically inflamed nasal epithelium reveals immune-epithelial dynamics and tissue remodeling in nasal polyp formation.
Liao G, Nakayama T, Zhu B, Lee IT, Yeung J, Yeo YY, Chang Y, Wang C, Liao SC, Nkosi D, Renteria A, Bravo DT, Overdevest JB, Yan CH, Zarabanda D, Gall PA, Dholakia SS, Borchard NA, Yang A, Kim D, Patel ZM, Hwang PH, Wagh D, Coller J, Phillips KM, Chang MT, Lechner M, Li Z, Yeh TH, Nolan G, Longhi MS, Boussiotis V, Barouch DH, Ma Q, Nayak JV, Jiang S.
Immunity. 2025 Oct 14;58(10):2593-2608.e6. doi: 10.1016/j.immuni.2025.08.009. Epub 2025 Sep 12.
PMID:40945518
Pathophysiology and management of Staphylococcus aureus in nasal polyp disease.